Pharmacogenetics of ACE inhibitor-induced angioedema and cough: A systematic review and meta-analysis

Pharmacogenomics

Volumn 14, Issue 3, 2013, Pages 249-260

  Mahmoudpour, Seyed Hamidreza ^a   Leusink, Maarten ^a   Putten, Lisa Van Der ^b   Terreehorst, Ingrid ^c   Asselbergs, Folkert W ^d   De Boer, Anthonius ^a   Maitland Van Der Zee, Anke H ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

ACE I D; ACEI; angioedema; cough; meta analysis

Indexed keywords

CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ACE GENE; ANGIONEUROTIC EDEMA; BDKRB2 GENE; COUGHING; ETHNICITY; GENE; GENE DELETION; GENE INSERTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HYPERTENSION; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; XPNPEP2 GENE;

ADULT; AGED; ANGIOEDEMA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COUGH; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RECEPTOR, BRADYKININ B2;

EID: 84873635879     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.206     Document Type: Review

References (58)

1. Khalil ME, Basher AW, Brown EJ Jr, Alhaddad IA. A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patients. J. Am. Coll. Cardiol. 37(7), 1757-1764 (2001).
2. Sarkar P, Nicholson G, Hall G. Brief review: angiotensin converting enzyme inhibitors and angioedema: anesthetic implications. Can. J. Anaesth. 53(10), 994-1003 (2006).
3. Morimoto T, Gandhi TK, Fiskio JM et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J. Eval. Clin. Pract. 10(4), 499-509 (2004).
4. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann. Intern. Med. 117(3), 234-242 (1992).
5. Wilkin JK, Hammond JJ, Kirkendall WM. The captopril-induced eruption. A possible mechanism: cutaneous kinin potentiation. Arch. Dermatol. 116(8), 902-905 (1980).
6. Bas M, Adams V, Suvorava T, Niehues T, Hoffmann TK, Kojda G. Nonallergic angioedema: role of bradykinin. Allergy 62(8), 842-856 (2007).
7. Dean DE, Schultz DL, Powers RH. Asphyxia due to angiotensin converting enzyme (ACE) inhibitor mediated angioedema of the tongue during the treatment of hypertensive heart disease. J. Forensic Sci. 46(5), 1239-1243 (2001).
8. Sanchez-Borges M, Gonzalez-Aveledo LA. Angiotensin-converting enzyme inhibitors and angioedema. Allergy Asthma Immunol. Res. 2(3), 195-198 (2010).
9. Weber MA, Messerli FH. Angiotensin-converting enzyme inhibitors and angioedema: estimating the risk. Hypertension 51(6), 1465-1467 (2008).
10. Nikpoor B, Duan QL, Rouleau GA. Acute adverse reactions associated with angiotensin-converting enzyme inhibitors: genetic factors and therapeutic implications. Expert Opin. Pharmacother. 6(11), 1851-1856 (2005).
11. Zamora SG, Parodi R. Cough and angioedema in patients receiving angiotensin-converting enzyme inhibitors. Are they always attributable to medication? Revista Argentina de Cardiologia 79(2), 157-163 (2011).
12. Chan WK, Chan TY, Luk WK, Leung VK, Li TH, Critchley JA. A high incidence of cough in Chinese subjects treated with angiotensin converting enzyme inhibitors. Eur. J. Clin. Pharmacol. 44(3), 299-300 (1993).
13. Woo KS, Nicholls MG. High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. Br. J. Clin. Pharmacol. 40(2), 141-144 (1995).
14. Burkhart DG, Brown NJ, Griffin MR, Ray WA, Hammerstrom T, Weiss S. Angiotensin converting enzyme inhibitor-associated angioedema: higher risk in blacks than whites. Pharmacoepidemiol. Drug Saf. 5(3), 149-154 (1996).
15. Mahoney EJ, Devaiah AK. Angioedema and angiotensin-converting enzyme inhibitors: are demographics a risk? Otolaryngol. Head Neck Surg. 139(1), 105-108 (2008).
16. Miller DR, Oliveria SA, Berlowitz DR, Fincke BG, Stang P, Lillienfeld DE. Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension 51(6), 1624-1630 (2008).
17. Kostis JB, Kim HJ, Rusnak J et al. Incidence and characteristics of angioedema associated with enalapril. Arch. Intern. Med. 165(14), 1637-1642 (2005).
18. Stroup DF, Berlin JA, Morton SC et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283(15), 2008-2012 (2000).
19. Duan QL, Nikpoor B, Dube M et al. A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. Am. J. Hum. Genet. 77(4), 617-626 (2005).
20. Cilia La Corte AL, Carter AM, Rice GI et al. A functional XPNPEP2 promoter haplotype leads to reduced plasma aminopeptidase P and increased risk of ACE inhibitor-induced angioedema. Hum. Mutat. 32(11), 1326-1331 (2011).
21. Woodard-Grice AV, Lucisano AC, Byrd JB, Stone ER, Simmons WH, Brown NJ. Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema. Pharmacogenet Genomics 20(9), 532-536 (2010).
22. Bas M, Hoffmann TK, Tiemann B et al. Potential genetic risk factors in angiotensin-converting enzyme-inhibitor-induced angio-oedema. Br. J. Clin. Pharmacol. 69(2), 179-186 (2010).
23. Gulec M, Caliskaner Z, Tunca Y et al. The role of ACE gene polymorphism in the development of angioedema secondary to angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. Allergol. Immunopathol. (Madr.) 36(3), 134-140 (2008).
24. Lee YJ, Tsai JC. Angiotensin-converting enzyme gene insertion/deletion, not bradykinin B2 receptor -58T/C gene polymorphism, associated with angiotensin-converting enzyme inhibitor-related cough in Chinese female patients with non-insulin-dependent diabetes mellitus. Metabolism 50(11), 1346-1350 (2001).
25. Grilo A, Saez-Rosas MP, Santos-Morano J et al. Identification of genetic factors associated with susceptibility to angiotensin-converting enzyme inhibitors-induced cough. Pharmacogenet Genomics 21(1), 10-17 (2011).
26. Mas S, Gasso P, Alvarez S et al. Pharmacogenetic predictors of angiotensin-converting enzyme inhibitor-induced cough: the role of ACE, ABO, and BDKRB2 genes. Pharmacogenet Genomics 21(9), 531-538 (2011).
27. Kim TB, Oh SY, Park HK et al. Polymorphisms in the neurokinin-2 receptor gene are associated with angiotensin-converting enzyme inhibitor-induced cough. J. Clin. Pharm. Ther. 34(4), 457-464 (2009).
28. Mukae S, Itoh S, Aoki S et al. Association of polymorphisms of the renin-angiotensin system and bradykinin B2 receptor with ACE-inhibitor-related cough. J. Hum. Hypertens. 16(12), 857-863 (2002).
29. Mukae S, Aoki S, Itoh S, Iwata T, Ueda H, Katagiri T. Bradykinin B(2) receptor gene polymorphism is associated with angiotensin-converting enzyme inhibitor-related cough. Hypertension 36(1), 127-131 (2000).
30. Zee RY, Rao VS, Paster RZ, Sweet CS, Lindpaintner K. Three candidate genes and angiotensin-converting enzyme inhibitor-related cough: a pharmacogenetic analysis. Hypertension 31(4), 925-928 (1998).
31. Woo SW, Bang S, Chung MW, Jin SK, Kim YS, Lee SH. Lack of association between ACE and bradykinin B2 receptor gene polymorphisms and ACE inhibitor-induced coughing in hypertensive Koreans. J. Clin. Pharm. Ther. 34(5), 561-567 (2009).
32. Nishio K, Kashiki S, Tachibana H, Kobayashi Y. Angiotensin-converting enzyme and bradykinin gene polymorphisms and cough: a meta-analysis. World J. Cardiol. 3(10), 329-336 (2011).
33. Furuya K, Yamagachi E, Hirabayashi T et al. Angiotensin-I-converting enzyme gene polymorphism and susceptibility to cough. Lancet 343(8893), 354 (1994).
34. Kreft-Jais C, Laforest L, Bonnardeaux A, Dumont C, Plouin PF, Jeunemaitre X. ACE inhibitors, cough, and genetics. Lancet 343(8899), 740 (1994).
35. Chadwick IG, Yeo WW, Higgins KS, Jackson PR, Ramsay LE, Morice AH. ACE-inhibitors, cough, and genetics. Lancet 343(8899), 740-741 (1994).
36. Okumura H, Nishimura E, Kariya S et al. No relation between angiotensin-converting enzyme (ACE) inhibitor-induced cough and ACE gene polymorphism, plasma bradykinin, substance P and ACE inhibitor concentration in Japanese patients. Yakugaku Zasshi 121(3), 253-257 (2001).
37. Lu J, Li LM, Zhan SY et al. Study on candidate genes of benazepril related cough in Chinese hypertensives. Zhonghua Liu Xing Bing Xue Za Zhi 24(6), 498-502 (2003).
38. Ye RJ, He QY, Gai J, Shang Y. A prospective study on the cough mechanism induced by angiotensin-converting enzyme inhibitors in patients with hypertension. Zhonghua Jie He He Hu Xi Za Zhi 27(9), 581-584 (2004).
39. Eleni S, Dimitrios K, Vaya P, Areti M, Norma V, Magdalini G. Angiotensin-I converting enzyme gene and I/D polymorphism distribution in the Greek population and a comparison with other European populations. J. Genet. 87(1), 91-93 (2008).
40. Copas J, Shi JQ. Meta-analysis, funnel plots and sensitivity analysis. Biostatistics 1(3), 247-262 (2000).
41. Campos MM, Calixto JB. Neurokinin mediation of edema and inflammation. Neuropeptides 34(5), 314-322 (2000).
42. Emanueli C, Grady EF, Madeddu P et al. Acute ACE inhibition causes plasma extravasation in mice that is mediated by bradykinin and Substance P. Hypertension 31(6), 1299-1304 (1998).
43. Boichot E, Biyah K, Germain N, Emonds-Alt X, Lagente V, Advenier C. Involvement of tachykinin NK1 and NK2 receptors in substance P-induced microvascular leakage hypersensitivity and airway hyperresponsiveness in guinea-pigs. Eur. Respir. J. 9(7), 1445-1450 (1996).
44. Lefebvre J, Murphey LJ, Hartert TV, Jiao Shan R, Simmons WH, Brown NJ. Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema. Hypertension 39(2 Pt 2), 460-464 (2002).
45. Byrd JB, Touzin K, Sile S et al. Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema. Hypertension 51(1), 141-147 (2008).
46. Adam A, Cugno M, Molinaro G, Perez M, Lepage Y, Agostoni A. Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. Lancet 359(9323), 2088-2089 (2002).
47. Tomaki M, Ichinose M, Miura M et al. Angiotensin converting enzyme (ACE) inhibitor-induced cough and substance P. Thorax 51(2), 199-201 (1996).
48. Van Guilder GP, Pretorius M, Luther JM et al. Bradykinin type 2 receptor BE1 genotype influences bradykinin-dependent vasodilation during angiotensin-converting enzyme inhibition. Hypertension 51(2), 454-459 (2008).
49. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet 351(9117), 1693-1697 (1998).
50. Molinaro G, Cugno M, Perez M et al. Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine(9)-bradykinin. J. Pharmacol. Exp. Ther. 303(1), 232-237 (2002).
51. Brown NJ, Blais C Jr, Gandhi SK, Adam A. ACE insertion/deletion genotype affects bradykinin metabolism. J. Cardiovasc. Pharmacol. 32(3), 373-377 (1998).
52. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J. Clin. Invest. 86(4), 1343-1346 (1990).
53. Tiret L, Rigat B, Visvikis S et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am. J. Hum. Genet. 51(1), 197-205 (1992).
54. Morice AH, Turley AJ, Linton TK. Human ACE gene polymorphism and distilled water induced cough. Thorax 52(2), 111-113 (1997).
55. Takahashi T, Yamaguchi E, Furuya K, Kawakami Y. The ACE gene polymorphism and cough threshold for capsaicin after cilazapril usage. Respir. Med. 95(2), 130-135 (2001).
56. Mc Garvey LP, Savage DA, Feeney SA et al. Is there an association between angiotensin-converting enzyme gene variants and chronic nonproductive cough? Chest 118(4), 1091-1094 (2000).
57. Li YF, Zhu XM, Liu F et al. Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism and ACE inhibitor-related cough: a meta-analysis. PLo S One 7(6), e37396 (2012).
58. Chung CM, Wang RY, Chen JW et al. A genome-wide association study identifies new loci for ACE activity: potential implications for response to ACE inhibitor. Pharmacogenomics J. 10(6), 537-544 (2010).